{
    "ticker": "GENN",
    "name": "Generex Biotechnology Corporation",
    "description": "Generex Biotechnology Corporation is a healthcare company focused on the commercialization of a proprietary platform for the development of therapeutic and vaccine products. Founded in 1997, the company is dedicated to improving the quality of life for patients through innovative healthcare solutions. Generex's flagship product is the Ii-Key peptide platform, which enhances the immune response and is being developed for various applications, including vaccines and immunotherapy treatments for diseases such as COVID-19 and cancer. The company is also involved in the development of diagnostic and therapeutic solutions for diabetes, leveraging its technology to create more effective treatment options. Generex is committed to advancing healthcare through research and development, partnering with leading institutions and organizations to bring its products to market. With a focus on patient-centric solutions, Generex aims to enhance the efficacy of therapies while reducing side effects, making healthcare more accessible and effective for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Toronto, Ontario, Canada",
    "founded": "1997",
    "website": "https://www.generex.com",
    "ceo": "Joseph Moscato",
    "social_media": {
        "twitter": "https://twitter.com/Generex",
        "linkedin": "https://www.linkedin.com/company/generex-biotechnology-corporation/"
    },
    "investor_relations": "https://www.generex.com/investor-relations",
    "key_executives": [
        {
            "name": "Joseph Moscato",
            "position": "CEO"
        },
        {
            "name": "Dr. Alvaro J. L. Rojas",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Ii-Key Peptide Platform",
                "Diabetes Treatment Solutions"
            ]
        },
        {
            "category": "Vaccines",
            "products": [
                "COVID-19 Vaccine Candidate"
            ]
        }
    ],
    "seo": {
        "meta_title": "Generex Biotechnology Corporation | Innovative Healthcare Solutions",
        "meta_description": "Generex Biotechnology Corporation focuses on developing therapeutic and vaccine products using its proprietary Ii-Key peptide platform. Explore Generex's commitment to enhancing healthcare.",
        "keywords": [
            "Generex",
            "Biotechnology",
            "Vaccines",
            "Therapeutics",
            "Healthcare Solutions",
            "Ii-Key Peptide"
        ]
    },
    "faq": [
        {
            "question": "What does Generex Biotechnology Corporation do?",
            "answer": "Generex is focused on the commercialization of therapeutic and vaccine products using its Ii-Key peptide platform."
        },
        {
            "question": "Who is the CEO of Generex?",
            "answer": "Joseph Moscato is the CEO of Generex Biotechnology Corporation."
        },
        {
            "question": "Where is Generex headquartered?",
            "answer": "Generex is headquartered in Toronto, Ontario, Canada."
        },
        {
            "question": "What are Generex's main product categories?",
            "answer": "Generex's main product categories include therapeutics and vaccines, with a focus on diabetes treatment and COVID-19 vaccine development."
        },
        {
            "question": "When was Generex founded?",
            "answer": "Generex was founded in 1997."
        }
    ],
    "competitors": [
        "NVAX",
        "MRNA",
        "BNTX",
        "VRTX"
    ],
    "related_stocks": [
        "AAPL",
        "AMZN",
        "MSFT",
        "GOOGL"
    ]
}